GAO Highlights Vulnerabilities in DEA and FDA Drug Scheduling Processes
Although DEA and HHS scheduling decisions aligned completely between 2020 and 2025, a new GAO report warns that missing agency policies and an outdated 40-year-old interagency agreement threaten operational consistency across federal drug oversight and defense health supply chains.
A new Government Accountability Office (GAO) report reveals that while the Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) maintain strong technical alignment on controlled substance scheduling, severe institutional policy gaps threaten long-term operational continuity. Between 2020 and 2025, the DEA conducted scheduling actions for 208 substances under the Controlled Substances Act, incorporating HHS scientific and medical evaluations for all 95 instances where consultation was statutorily mandated. Of the 84 finalized rulemakings completed during this six-year period, DEA scheduling decisions achieved a 100 percent alignment rate with HHS recommendations, with the remaining 11 substances maintained under active temporary scheduling orders.
Despite this surface-level harmony, the GAO uncovered critical governance deficiencies across participating agencies. The DEA currently lacks formalized internal policies outlining clear roles, responsibilities, and procedural benchmarks for executing scheduling determinations. Similarly, the Food and Drug Administration (FDA) operates without standardized written protocols governing how its scientific personnel conduct medical evaluations or formulate drug risk recommendations. Compounding these internal vulnerabilities, the foundational Memorandum of Understanding (MOU) establishing consultation protocols between the FDA and the National Institute on Drug Abuse (NIDA) has not been updated in over four decades, failing to reflect modern interagency structures, research methodologies, or administrative workflows.
For defense, government, and industry leaders overseeing strategic pharmaceutical stockpiles and mission health operations, these governance voids introduce unmanaged systemic risk. The present framework relies heavily on informal coordination and institutional memory rather than standardized regulatory infrastructure. Should key personnel with deep domain expertise depart, the absence of written procedures risks operational paralysis, regulatory bottlenecks, and potential friction between law enforcement authorities and defense acquisition channels. Such vulnerabilities directly impact the procurement cadence of specialized therapeutics, medical countermeasures, bio-defense capabilities, and military health system supply chains.
The GAO highlights the urgent need for both agencies to codify detailed internal policies governing scientific evaluations and administrative scheduling workflows. Furthermore, HHS and NIDA must immediately modernize their 40-year-old agreement to ensure expert addiction research consistently informs future federal drug scheduling. Establishing transparent, repeatable interagency mechanisms is vital to securing national defense medical supply chains and maintaining regulatory agility against emerging chemical and biological threats. (Source: GAO Reports)
Executive takeaway
Subscribe to receive signals like this — plus the executive analysis behind them.
Get the Signals